Press releasePRNewswire
Soligenix
SNGX · NASDAQ
$0.3546+$0.0109 (+3.17%)TodayMarket closed ·
Prev close $0.3437
Latest news
- Press releasePRNewswire
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results
- NewsAvi Kapoor
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
- NewsMohd Haider
Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releasePRNewswire
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
- Press releasePRNewswire
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains Over 3%; General Motors Earnings Top Views
- NewsVandana Singh
Why Is Soligenix Stock Sinking Tuesday?
- NewsAvi Kapoor
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
- Press releasePRNewswire
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
- Press releasePRNewswire
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
- Press releasePRNewswire
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
- Press releasePRNewswire
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
- Press releaseGlobe Newswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
- Press releasePRNewswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
- News
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
- Press releasePRNewswire
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
- Press releasePRNewswire
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
- Press releasePRNewswire
Soligenix to Present at BIO Investment & Growth Summit
- Press releasePRNewswire
Soligenix Details Recent Progress and Upcoming Milestones
- Press releasePRNewswire
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
- Press releasePRNewswire
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
- Press releaseGlobe Newswire
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease
- Press releaseGlobe Newswire
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
- Press releaseGlobe Newswire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
- Press releaseGlobe Newswire
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
- Press releaseGlobe Newswire
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
- NewsAvi Kapoor
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.